Q2 2025 OptimizeRx Corp Earnings Call Transcript
Key Points
- OptimizeRx Corp (OPRX) reported a strong second quarter of 2025 with revenues increasing 55% year-over-year to $29.2 million.
- The company achieved an adjusted EBITDA of $5.8 million, an improvement of over $5 million year-over-year.
- Contracted revenue increased by more than 30% year-over-year, positioning the company favorably for the second half of 2025.
- OptimizeRx Corp (OPRX) increased its guidance for the year, expecting revenue between $104 million and $108 million, with adjusted EBITDA between $14.5 million and $17.5 million.
- The company paid down $4.5 million of principal during the second quarter, which was $4 million above its debt payment schedule, indicating strong free cash flow and financial health.
- The company acknowledged that some of the revenue growth in the first half of 2025 was due to managed service revenue, which is not expected to continue into the second half.
- Operating expenses remained flat year-over-year at $15.4 million, despite significant revenue growth, which may not be sustainable in the long term.
- The concentration of revenue from the top 20 pharmaceutical manufacturers decreased, indicating a potential shift in revenue sources.
- The company did not provide specific details on the percentage of revenue that is subscription-based, which could impact visibility into future revenue streams.
- There is uncertainty in the macro environment, including regulatory headwinds for pharmaceutical companies, which could impact future business operations.
Good afternoon, everyone, and thank you for joining OptimizeRx's second-quarter fiscal 2025 earnings conference call. We have with us today Chief Executive Officer, Steve Silvestro, he is joined by Chief Financial Officer, Ed Stelmakh, Chief Legal Officer; Marion Odence-Ford; and Senior Vice President of Corporate Finance, Andrew D'Silva. At the conclusion of today's call, I will provide some important cautions regarding the forward-looking statements made by management during today's call. The company will also be discussing certain non-GAAP financial measures, which it believes are useful in evaluating the company's operating results. A reconciliation of such non-GAAP financial measures is included in the earnings release the company issued this afternoon as well as in the Investor Relations section of the company's website.
I would like to remind everyone that today's call is being recorded and will be made available for replay as an audio recording of this conference call on the Investor Relations section of the company's website. Now I would like to turn the call over to OptimizeRx's CEO,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
